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Abstract: In idiopathic trigeminal neuralgia (TN) the neuroimaging evaluation is usually 
 normal, but in some cases a vascular compression of trigeminal nerve root is present. Although 
the latter condition may be referred to surgery, drug therapy is usually the first approach to control 
pain. This study compared the clinical outcome and direct costs of (1) a traditional treatment 
(carbamazepine [CBZ] in monotherapy [CBZ protocol]), (2) the association of gabapentin (GBP) 
and analgesic block of trigger-points with ropivacaine (ROP) (GBP+ROP protocol), and (3) a 
common TN surgery, microvascular decompression of the trigeminal nerve (MVD protocol). 
Sixty-two TN patients were randomly treated during 4 weeks (CBZ [n = 23] and GBP+ROP 
[n = 17] protocols) from cases of idiopathic TN, or selected for MVD surgery (n = 22) due to 
intractable pain. Direct medical cost estimates were determined by the price of drugs in 2008 
and the hospital costs. Pain was evaluated using the Numerical Rating Scale (NRS) and number 
of pain crises; the Hospital Anxiety and Depression Scale, Sickness Impact Profile, and satisfac-
tion with treatment and hospital team were evaluated. Assessments were performed at day 0 and 
6 months after the beginning of treatment. All protocols showed a clinical improvement of pain 
control at month 6. The GBP+ROP protocol was the least expensive treatment, whereas surgery 
was the most expensive. With time, however, GBP+ROP tended to be the most and MVD the 
least expensive. No sequelae resulted in any patient after drug  therapies, while after MDV sur-
gery several patients showed important side effects. Data reinforce that, (1) TN patients should 
be carefully evaluated before choosing therapy for pain control, (2) different pharmacological 
approaches are available to initiate pain control at low costs, and (3) criteria for surgical inter-
ventions should be clearly defined due to important side effects, with the initial higher costs 
being strongly reduced with time.
Keywords: trigeminal neuralgia,  carbamazepine, gabapentin associated with ropivacaine, 
 microvascular decompression, clinical outcomes, direct costs
Introduction
Trigeminal neuralgia (TN) is a neuropathic pathology considered one of the most 
painful experiences patients can report, and no universal treatment is capable of 
reverting completely and definitely its intermittent paroxysmal excruciating pain 
crises.1 TN is associated with impairment of daily functionality, reduced quality of 
life,2,3 and depression,4 to which contributes the overwhelming fear that pain can 
suddenly return again.  Although the huge impact of pain in TN, which has an inci-
dence of 4–5 per 100,0005 or even higher,6 and a high prevalence in older patients 
should have been capable of resulting in clinical standards for TN treatment, this 
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pathology is far from being well known and treated. In 
most cases the pathophysiology underlying TN is unknown 
or incompletely understood. Classical or idiopathic TN 
includes all cases without an established etiology (most 
of them) as well as those with potential vascular compres-
sion of the trigeminal nerve, whereas symptomatic TN 
results secondarily to cases such as tumors or multiple 
sclerosis.7
TN is not controlled by classical analgesics, but the 
f irst-line therapy is pharmacological, being based on 
 anticonvulsants (ACs), usually considered adjuvant  analgesics 
in other pathologies but essential for  neuropathic pain. Phe-
nytoin in the past8,9 and now  carbamazepine (CBZ)1,10–12 are 
first-line drugs in TN, followed by several second-line ACs 
such as lamotrigine,11,13 oxcarbazepine,14 gabapentin (GBP),1 
and CBZ or GBP associated with peripheral block of  trigger-
points with the local anesthetic ropivacaine (ROP);3,15 these 
treatments changed the management of TN, as previously 
it was almost exclusively surgical. Surprisingly, combina-
tion therapies, although common in epilepsy, have not been 
explored for TN management.3,15,16
Surgical intervention for TN is usually reserved for 
patients with intractable pain refractory to an adequate trial 
of at least 3 drugs including CBZ.1 The decision to perform 
a surgical approach should be based on the clinical pre-
sentation (including co-morbilities) of the patient and not 
primarily or exclusively on neuroimaging,1 as craniotomy 
is not without risks and fine detail alone at actual MRI 
spatial resolution cannot distinguish the pathological from 
the incidental when a vessel course is along the trigeminal 
nerve root.17,18  However, some patients may request sur-
gical treatment due to intractable pain or strong adverse 
side effects.1  Microvascular decompression (MVD) of the 
trigeminal nerve root is a well established and superior 
method of choice among  neurosurgical procedures19 in 
immediate (91%–97%) and long-term (53%–70%) relief of 
TN,12,20–22 but is associated with several risks, including dif-
ferent degrees of facial sensory loss as well as a small risk 
of mortality.1 Other  surgical options include Gasser ganglion 
compression,  glycerol gangliolysis, and radiofrequency ther-
mocoagulation of the nerve, with the last producing initial 
pain relief in more than 90% and a complete pain relief after 
5 years reaching 57% of patients;23 however, these cases are 
associated with a risk of anesthesia dolorosa (0.6%–6%) 
and cases of transient or permanent cranial nerve palsies.1,23 
Gamma knife radiosurgery is less invasive, the onset of pain 
relief following procedure possibly requiring 1–2 months to 
occur, but then 30%–80% of cases report complete absence 
of pain;24–27  however, again, frequency of paresthesia and 
dysesthesia ranges from 3%–54%,28,29 there is a steady rate 
of late failure,25 and the details of operative technique have 
a major influence on the clinical results.30,31 Nevertheless, 
in radiosurgical centers, this is a major surgery treatment 
for TN.27
From the above data, we should consider that the choice 
of drug and whether or not to operate and which procedure 
to choose should be individualized to the particular needs 
and conditions of each patient.1 The role of surgery versus 
pharmacotherapy in TN management remains uncertain 
as there are no studies dealing specifically with issues like 
“when should surgery be offered?”.12 Additionally, only a 
few studies have evaluated the impact of TN costs to the 
patients, and compared only the cost-effectiveness of differ-
ent surgical procedures. At longer follow-up intervals, MVD 
is predicted to be the most cost-effective surgery and should 
be considered the preferred operation for patients, compared 
with glycerol rhizotomy and stereotactic radiosurgery,32 
whereas cyberknife radiosurgery is a cost-saving alternative 
compared with MVD.33 On the other hand, to the best of our 
knowledge, the costs associated with TN drug treatments have 
been analyzed only for pregabalin.34,35 However, no studies 
have evaluated the costs associated with different drug treat-
ments compared with surgery. The objective of the present 
study was to compare the clinical outcome and direct costs 
of (1) a first-line pharmacological treatment (CBZ), (2) the 
therapeutical association of GBP and the peripheral analgesic 
block of TN trigger-points with ROP (GBP+ROP) and (3) a 
common TN surgery (MDV) in patients recruited from the 
same country region.
Methods
Patients – inclusion and exclusion criteria
This retrospective study includes a total of 62 TN patients 
from the Hospital Center of Alto Ave – Fafe Pain Unit and 
the Hospital São Marcos in Braga, who were selected by dif-
ferent clinical teams as follows: patients under the traditional 
approach to TN were given CBZ in monotherapy (CBZ 
 protocol; n = 23) and were randomly selected in the continu-
ation of a previous study of our group;15 patients submitted to 
an alternative TN approach were given GBP associated with 
the peripheral analgesic block of trigger-points with ROP 
(GBP+ROP protocol; n = 17) and were randomly selected 
in the continuation of another previous study of our group;3 
patients submitted to microvascular decompression of the 
trigeminal nerve (MVD protocol; n = 22) were all those arriv-
ing at the Neurosurgery Department of Hospital São Marcos 
Journal of Pain Research 2011:4
Table 1 Baseline characteristics of the patients
Protocol GBP+ROP  
(n = 17)
Protocol CBZ  
(n = 23)
Protocol MVD surgery 
(n = 22)
Age (years, average and sD) 63 (16.3) 66 (10.8) 66 (9.3)
gender (women/total) 12/17 19/23 15/22
Pain location (trigeminal branches)
 V1 or V2 or V3 7 13 6
 V1 + V2 or V2 + V3 6 7 9
 V1 + V2 + V3 4 3 7
Facial side (right/total) 12/17 10/23 11/22
Pain duration at day 0
 1–5 years 13 9 4
 6–10 years 4 5 14
 $11 years 0 9 4
Abbreviations: gBP+ROP, gabapentin+ropivacaine; cBZ, carbamazepine; MVD, microvascular decompression.
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between 2005 and 2008 and indicated for surgery by this 
Hospital team (Table 1).
Patients from CBZ and GBP+ROP protocols were 
 eligible for the study if they presented a pain intensity 
with a score $ 6 measured by the Numerical Rating Scale 
(NRS), and met the consensus criteria for the diagnosis 
of primary (idiopathic) TN.36 The inclusion criteria were 
(1) the occurrence of episodes of facial paroxysmal pain in 
territory innervated by a branch of the trigeminal nerve (NRS 
score $ 6), (2) presence of a normal neurological profile, 
and (3) presence of normal neuroimaging analysis. On the 
other hand, several exclusion criteria were also considered,3,15 
including patient refusal to participate, clinical depressive 
condition, anticlotting therapy, secondary (symptomatic) 
TN, altered neurological profile, neuroimaging alterations, 
association with other cranial nerve neuralgias, and proposed 
surgical intervention.
Patients following the surgical protocol (MVD) were 
selected by their intense intractable pain refractory to pharma-
cological therapy, or intolerable side effects of drugs.37 Thus, 
when arriving at the Neurosurgery Department of Hospital São 
Marcos (day 0), 21 of 22 patients showed NRS = 10 and all 
were being medicated (12 patients were taking 600 mg/day of 
CBZ and 10 were taking 600 mg/day of CBZ plus 600 mg/day 
of GBP). This Neurosurgery Department does not have equip-
ment for radiosurgery, thus MVD constitutes the major surgical 
approach for TN patients with intractable pain.
The therapeutical protocols used were accepted by the 
Hospital Ethical Committees (all three are actual therapies 
for TN pain control) and the patients were informed by the 
different clinical teams that: (1) they were going to be sub-
mitted to one of three (GBP+ROP protocol; see reference 3) 
or one of two (CBZ protocol15) pharmacological therapies, 
or to surgery (MVD protocol); (2) they could drop or 
change treatment if no pain control was achieved (CBZ and 
GBP+ROP protocols) or they would be continuing to take 
pharmacological agents if needed (MDV protocol). Patients 
signed an informed consent.
Treatment protocols
Patients were submitted to one of the following treatment 
protocols:
CBZ protocol – Treatment using only oral CBZ in mono-
therapy; patients entering this protocol received additionally 
a control injection of saline (the vehicle of ROP administered 
to the other protocol, CBZ+ROP applied in another study15) at 
facial trigger-points each 7 days of treatment (days 0, 7, 14, 
21, and 28), during 4 weeks. The usual effective CBZ dos-
age ranges from 400 to 1000 mg/day.38 Since these patients 
arrived at the Fafe Pain Unit from other Health Institutions 
with uncontrolled pain (day 0), their CBZ dose (whatever 
it was) was increased by 200 mg/day; thus, no CBZ titra-
tion was performed. Each 7 days, during their visit to the 
Unit, the NRS score of the patients was recorded and CBZ 
dose adjusted if necessary. For statistical purposes patients 
were evaluated at day 0 (arrival to the pain unit) and after a 
follow-up of 5 months after the end of the 4-week treatment 
(month 6).
GBP+ROP protocol – Treatment using oral GBP plus 
administration of a superficial analgesic block with ROP to 
facial trigger-points, as described elsewhere.3 The periph-
eral block with ROP was performed at the Pain Unit under 
sterile conditions, using a 27-gauge needle for administer-
ing subcutaneously 2 mL of a 2 mg/mL ROP solution.3,39 
Each local block was peformed once a week3,40 during the 
1-month therapy (days 0, 7, 14, 21, and 28, when the patient 
was received by the Unit staff). At day 0, an ROP block 
was performed and 100 mg GBP administered at night 
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to each patient. On subsequent days, daily GBP increase 
followed the rationale described in Lemos et al.3 For statistical 
purposes patients were evaluated at day 0 (arrival to the pain 
unit) and after a follow-up of 5 months (month 6).
MVD protocol – This technique is thoroughly described 
elsewhere.37 During pre-surgery, MVD patients undergo tests 
(blood, electrocardiogram, chest X-ray, computed tomogra-
phy (CT scan)) several days before surgery. During surgery, 
patients are anesthetized always using the same protocol 
(endovenous general anesthesia) and are positioned on their 
back with their head turned or on their side with the symp-
tomatic side facing up. A vertical incision is made behind 
the ear, 3–5 mm medial to the mastoid notch and extending 
about the length of the ear. A circular portion of the skull is 
removed exposing the underlying dura, which is opened to 
expose the cerebellum and reach the posterior fossa. The cer-
ebellum is allowed to fall out of the way exposing the side of 
the brainstem. By advancing over the superior surface of the 
cerebellum, the VII and VIII cranial nerves are avoided. The 
arachnoid membrane is dissected allowing visualization of 
the VII, VIII, and finally the trigeminal nerve. The offending 
loop of blood vessel is then mobilized. Venous vessels above 
or below the nerve are dissected away from the nerve and 
are coagulated and divided if needed. A sponge-like material 
(Teflon) is inserted between the vessel in contact with the 
nerve (usually the superior cerebellar artery).41 Frequently a 
groove or indentation is seen in the nerve where the offending 
vessel was in contact with the nerve. The sponge-like material 
is placed between the nerve and the offending blood vessel 
to prevent the vessel from returning to its native position. 
If venous vessels alone are in contact with the nerve, no 
prosthesis is required as they are coagulated and divided.37 
After the decompression is complete, the wound is flushed 
clean with saline solution. The dura is sewn closed. The 
skull is reconstructed and the overlying tissues are closed 
in multiple layers. The patient is allowed to wake up and is 
taken to an intensive care unit or other close observation unit 
for 3–5 days before returning home. For statistical purposes 
patients were evaluated at day 0 (day before surgery) and 
after a follow-up of 6 months (month 6).
clinical outcome
The predefined outcome measures were:
1.	 Evaluation of pain intensity using the NRS scale. 
 Evaluation points were the following: at the arrival at 
the Pain Unit (CBZ and GBP+ROP protocols) or the 
day before surgery at the Neurosurgical Department 
(MVD protocol) (day 0) and 6 months later (month 6). 
Patients were told to locate their relative pain in a line 
marked with numbers, from 0 (no pain) in the extrem-
ity on the left to 10 (the worst pain imaginable) in the 
extremity on the right. Moderate pain was considered 
to be . 3 (NRS . 3) and severe pain . 6 (NRS . 6).42 
A pain reduction of 2 points in the 11-point NRS scale 
from the baseline pain score (day 0) was considered to 
be clinically significant.43–45
2.	 Daily number or paroxysmal pain episodes. Although this 
variable was evaluated every day, only data obtained at 
day 0 and month 6 were used for statistical analysis.
3.	 Adverse side effects, especially those involving sensory 
alterations. For each patient of the protocols evalu-
ated, the types of sensory deficits were recorded before 
(day 0) and 6 months after the beginning of therapeutical 
intervention.
4.	 The Hospital Anxiety and Depression Scale (HADS) 
questionnaire46,47 is a self-screening evaluation for depres-
sion and anxiety. It consists of 14 questions, 7 for anxiety 
and 7 for depression, which were presented to patients of 
the three protocols at day 0 and month 6.
5.	 Evaluation of life quality using the Sickness Impact 
Profile (SIP).48–50 This questionnaire, adapted to the Portu-
guese population,49 evaluated the evolution of the quality 
of life of patients submitted to the three protocols, from 
day 0 to month 6. SIP evaluates the descriptive profile 
of patients in terms of impact of the pathology ana-
lyzed upon specific daily life behaviors. We analyzed the 
answers obtained at day 0 and month 6 to 136 questions 
distributed along the following categories: “Domestic 
Work”, “Mobility”, “Communication”, “Locomotion”, 
“Eating”, “Recreation-Pastimes”, “Emotion”, “Social 
Interaction”, “Alertness”, and “Rest”.
6.	 Questionnaire on the satisfaction with the treatment and 
medical team (QUASU). It contains 47 items that evaluate 
patient satisfaction at different levels: Access, Expenses, 
Technical Quality, Communication/ Information, Interper-
sonal Relations, Team Coordination, and Global Evalua-
tion (created by McIntyre et al51 based on the Portuguese 
population).
The follow-up evaluation was performed at the end of  the 
day, on completion of month 6, during a phone interview to 
each patient. For NRS evaluation the patient was asked to 
reveal (1) the pain felt at that moment as a number on the NRS 
scale with which they were used to dealing with or, in case of 
no pain, (2) which was the pain felt in the worst day of the last 
week before the interview. For the number of pain crisis, each 
patient was asked (3) how many pain attacks they had suffered 
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Table 2 Average direct healthcare cost per patient
Protocol Cost category 1st  
month (€)
2nd–6th  
month (€)*
gBP+ROP gBP 7.29 109.2
1st consultation 71.42
Other consultations 205.1
3 sessions 75.81
imaging tests 79.55
Laboratory tests 18.40
Total 252.47 (0) 314.3 (0)
cBZ cBZ 9.9 49.9
1st consultation 71.42
Other consultations 205.10 205.1
imaging tests 79.55
Laboratory tests 18.40
Total 384.2 (1.5) 255.0 (6.3)
MVD cBZ+gBP 30.39 49.6
surgery 719.90
1st consultation 71.42
Other consultations 137.12 205.1
imaging tests 79.55
Laboratory tests
Total 1056.78 (22.3) 254.7 (40.9)
Notes: *sum of costs over 5 months (months 2–6); values in parentheses = standard 
deviation.
Abbreviations: gBP+ROP, gabapentin+ropivacaine; cBZ, carbamazepine; MVD, 
microvascular decompression.
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during that day or, in case of no pain, (4) how many pain crises 
they had suffered in the worst day of the last week before the 
interview. If no pain was recorded following these four ques-
tions, the staff recorded 0 (zero) pain crisis for the patient. 
The adverse side effects were also recorded and patients 
completed the SIP and HADS questionnaires.
Direct cost analysis: pharmacological  
and hospital costs
For patients submitted to pharmacological (CBZ and 
GBP+ROP protocols) or surgical (MVD protocol) therapies, 
direct medical cost estimates were determined using hospital 
cost accounting data published in Diário da República, the 
“Simposium Terapêutico 2008”, and the price lists included in 
the latter.52,53 Medical costs were calculated using the patient-
reported dosage and number of doses taken daily and Hospital 
internment, which were converted to the cost between day 0 
and 1 month (according to the 4-week treatment in protocols 
GBP+ROP and CBZ) and between month 1 and month 6 
(follow-up for the three protocols) (Table 2).
statistics
Data are presented as mean ± standard deviation (SD) along 
the several variables under study. The normal distribution 
of the results was verified using the Kolmogorov–Smirnov 
test, whereas the equality of variances was evaluated by 
the Levene test. A logarithmic transformation of data has 
been used whenever the homogeneity of variances was not 
 verified. Mean NRS scores, number of pain crisis, direct 
costs, SIP, and HADS values at day 0 and month 6 (or only at 
month 6 for costs data) were compared using paired-samples 
Student’s t-test whenever possible, or the one-sample t-test 
when one of the means showed absence of variation (see 
Results section). Mean NRS scores following protocols CBZ, 
GBP+ROP, and MVD were compared at month 6 using a 
one-way analysis of variance (ANOVA) followed by the 
Tukey post hoc test.
Results
Patient baseline characteristics
The baseline data for the demographic characteristics 
of patients selected for the three protocols are shown in 
Table 1.
effect of cBZ, gBP+ROP and MVD 
protocols in pain control
No differences in pain intensity were found between patients 
from GBP+ROP protocol (NRS
d0
 = 8.8 ± 1.4) and CBZ 
protocol (NRS
d0
 = 9.1 ± 1.4) (P = 0.41, t-test) (Figure 1) at 
the beginning of the treatment [day 0 (d0)], whereas 21 of 
22 MVD patients presented an NRS score of 10, the most 
painful condition imaginable (NRS
d0
 = 9.9 ± 0.4). Five 
months after the 4-week treatment followed in CBZ and 
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Figure 1 effect of the three protocols (gBP+ROP, cBZ, and MVD) on the pain 
intensity of patients 6 months after day 0. For significant differences see the 
Results section.
Abbreviations: gBP+ROP, gabapentin+ropivacaine; cBZ, carbamazepine; MVD, 
microvascular decompression; nRs, national Rating scale.
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GBP+ROP protocols [month 6 (6m)], both pharmacologi-
cal approaches had decreased significantly, pain measured 
by NRS scores (GBP+ROP
d0
 × GBP+ROP
6m
, P , 0.0001; 
CBZ
0
 × CBZ
6m
, P , 0.0001, paired-samples t-tests), while 
6 months after MVD surgery NRS scores were also signifi-
cantly reduced (MDV
d0
 × MDV
6m
, P , 0.001, one-sample 
t-test). Although the three protocols reduced pain intensity, 
GBP+ROP therapy resulted in a significantly lower NRS 
score than patients following CBZ or MVD protocols 
(GBP+ROP, NRS
6m
 = 2.6 ± 1.00; CBZ, NRS
6m
 = 3.9 ± 1.5; 
MVD, NRS
6m
 = 4.2 ± 1.7, one-way ANOVA, P = 0.002; 
GBP+ROP
6m
 × CBZ
6m
, P = 0.011, GBP+ROP
6m
 × MVD
6m
, 
P = 0.002, Tukey tests) (Figure 1). With respect to the NRS 
observed at month 6 for MVD patients, it can be concluded 
by a one-sample t-test that the NRS value is significantly 
different from 10 (P , 0.001), the value observed before 
surgery (day 0).
The baseline number of daily crises of paroxysmal sudden 
and intense pain was similar between patients of both phar-
macological protocols (day 0: GBP+ROP, n
crises
 = 9.6 ± 1.5; 
CBZ, n
crises
 = 10.7 ± 2.2; P = 0.114, t-test), whereas 21 of 
22 MVD patients presented 12 pain crises per day (MVD, 
n
crisis
 = 11.8 ± 0.6) (Figure 2). Five months after the 4-week treat-
ment followed in CBZ and GBP+ROP protocols (month 6), all 
three protocols had decreased significantly the number of daily 
pain crises (month 6: GBZ+ROP, n
crises
 = 2.0 ± 1.6; CBZ, n
crises
 
= 4.1 ± 1.7; MVD, n
crisis
 = 2.6 ± 0.6  -  GBP+ROP
d0
 × GBP+ROP
6m
, 
P , 0.0001; CBZ
d0
 × CBZ
6m
, P , 0.0001, paired samples 
t-tests; MDV
d0
 × MDV
6m
, P , 0.001, one-sample t-test) 
 (Figure 2). Again, with respect to the number of daily pain 
crises observed at month 6 in MVD patients, it can be con-
cluded by a one-sample t-test that the number of crises is 
significantly different from 12 (P , 0.001), the value observed 
before surgery (day 0).
Daily dose of anticonvulsants
The three protocols showed a different evolution in the 
consumption of anticonvulsants CBZ or GBP. At day 0 and 1 
GBP+ROP patients took 100 mg/day of GBP; at day 7, these 
patients were taking 200 or 300 mg/day (mean = 266,67 mg/day); 
at the end of the 4-week treatment patients were taking 
300 mg/day of GBP, which was maintained during the next 
5 months, until month 6.3 Patients following CBZ protocol 
arrived to the Hospital and began taking 626 ± 163 mg/day 
of CBZ; at the end of the 4-week treatment, CBZ intake 
increased to 757 ± 200 mg/day, which was increased even 
at month 6 to 826 ± 291 mg/day.15 Finally, MVD protocol 
patients were taking 600 mg/day of CBZ in monotherapy 
(12 of the 22 patients) or GBP+ROP (600 + 600 mg/day); at 
the end of the follow-up (month 6), MVD patients were still 
assisted by drugs, although at lower doses, namely 200 mg/
day of CBZ or 300 mg/day of GBP, both in monotherapy.
Adverse side effects
The GBP+ROP protocol resulted in no significant side 
effects and no sensory deficits.3 Patients following the CBZ 
protocol showed no sensory deficits, but 7 of the 21 patients 
presented adverse side effects (dizziness).15 On the contrary, 
5 of the 22 patients submitted to MVD protocol presented 
hypesthesia of the hemiface affected, 3 were anesthetized 
in the hemiface, 1 showed paresthesias, and 1 patient died in 
the immediate postoperative period due to brain hemorrhage, 
with a total of 10 in 22 patients with sensory sequelae; 
additionally, 5 of the 22 patients presented dizziness as an 
adverse side effect and 7 in 22 showed a complete absence 
of side effects or sequelae.
Direct costs
Data on direct costs of resources consumption show 
that MVD full cost was €1056.78 ± 22.5 per patient 
while, on the  contrary, CBZ (€384.2 ± 1.5) and espe-
cially GBP+ROP (€252.47) were far less expensive 
between day 0 (before treatment/surgery) and the end 
of the first month (GBP+ROP
euro
 × CBZ
euro
, P , 0.0001; 
GBP+ROP
euro
 × MVD
euro
, P , 0.0001, one-sample t-tests; 
CBZ
euro
 × MVD
euro
, P , 0.0001, paired-samples t-test) 
(Table 2). It can be concluded by one-sample t-tests that 
14
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Figure 2 effect of the three protocols (gBP+ROP, cBZ, and MVD) on number of 
daily episodes of pain before (day 0) and after a 5-month follow-up (month 6). For 
significant differences see the Results section.
Abbreviations: gBP+ROP, gabapentin+ropivacaine; cBZ, carbamazepine; MVD, 
microvascular decompression.
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the total direct cost during the first month per patient 
submitted to CBZ or MVD protocols is significantly dif-
ferent from €252.47 (P , 0.001), the average total cost 
value observed for each GBP+ROP patient. The difference 
is mostly explained by 2 factors: the cost of the surgical 
procedure and the cost of hospital stay for MVD patients. 
However, during months 2–5, the financial situation alters: 
GBP+ROP protocol becomes the most expensive treatment 
(GBP+ROP
months 2–6
 = €314.3), as GBP is more expensive than 
CBZ (CBZ
months 2–6
 = €255.0 ± 6.3) and MVD patients take a 
low dosage of anticonvulsants (MVD
months 2–6
 = €254.7 ± 40.9) 
(Table 2).
Functional quality of life  
and patient satisfaction
Quality of life measured by the scores obtained through the 
SIP questionnaire for patients in both GBP+ROP and CBZ 
protocols showed a significant improvement in functionality 
(GBP+ROP
d0
 × GBP+ROP
6m
, P , 0.0001), which was not 
achieved at a significant level by MVD patients (MVD
d0
 ×	MVD
6m
, 
P = 0.086, paired-samples t-tests) (Figure 3A). Interestingly, 
however, both anxiety and depression scores were signifi-
cantly improved in MVD patients from day 0 to month 6, as 
measured by HADS questionnaire (MVD
ANXd0
 × MVD
ANX6m
, 
P , 0.001; MVD
DEPd0
 × MVD
DEP6m
, P , 0.0001, paired-
samples t-test) (Figures 3B and 3C), whereas CBZ patients 
showed a significant improvement only in anxiety scores 
(CBZ
ANXd0
 × CBZ
ANX6m
, P = 0.036, paired-samples t-test) and 
GBP+ROP patients did not improve in any of the  dimensions 
evaluated by the HADS questionnaire  (Figures 3B and 3C).
The satisfaction of the patients with the treatment and 
with the clinical team, measured by the QUASU question-
naire, revealed a complete or high level of satisfaction of 
patients (Figure 4). While all patients allocated to protocols 
GBP+ROP and CBZ were totally satisfied with the treatment 
and clinical team, 5 out of 22 MVD patients were acceptably 
satisfied or unsatisfied with the treatment (Figure 4A) due to 
sensory adverse side effects, and 2/22 MVD patients were 
just acceptably satisfied with the team (Figure 4B).
Discussion
Economic evaluation of different therapeutical approaches 
is intended to support health-related decision-making by 
informing clinical decision-makers of estimates of costs and 
benefits of surgery and comparing them with the prevalent 
pharmacological intervention. Although the three branches of 
the present study were randomly obtained at 3 different times, 
the clinical outcomes obtained and the direct costs associated 
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reinforce the necessity of careful evaluation of the patient 
before the decision to make an invasive surgical  intervention. 
All protocols, GBP+ROP, CBZ, and MVD, decreased pain 
behavior significantly in TN patients, as measured by the 
NRS scale and number of daily pain crises, and total or a high 
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 satisfaction with both the treatment and clinical team was 
achieved. However, the degree of adverse side effects was dif-
ferent between protocols, GBP+ROP showing no side effects 
and MVD presenting several facial sensorial deficits, with dif-
ferent levels of severity. Additionally, during the first month of 
treatment, a much higher cost was attributed to MDV protocol 
due to surgical procedures, hospital stay, and maintenance of 
drug therapy, whereas pharmacotherapy costs were mainly 
drug costs. On the contrary, during the follow-up the surgical 
protocol was the less costly protocol and GBP+ROP was the 
most expensive, indicating that in longer follow-ups the MVD 
is less expensive than a prolonged drug treatment.
Methodological considerations
The rationale of the present study was to compare the 
efficacy of different therapeutical approaches to TN and 
evaluate the direct costs associated with each one. The 
GBP+ROP protocol was chosen due to its improved effi-
cacy as an association of an anticonvulsant and the analge-
sic block of TN trigger-points,3 which can constitute a valid 
alternative whenever the classic first-choice pharmacologi-
cal treatment, CBZ in monotherapy,1 cannot be used. The 
CBZ protocol is still considered the first-line choice for 
TN treatment.1,54–56 In order to eliminate the possibility that 
any beneficial effect could depend on the physical action 
of local administration of the analgesic ROP solution by 
clearing adhesions or inflammatory molecules from the 
vicinity of the nerve,40 the CBZ protocol was accompa-
nied by injection of saline to TN trigger-points. Thus, the 
improvements observed in the different outcomes analyzed 
resulted exclusively from the pharmacological action of 
GBP+ROP and CBZ and not from the manipulation and 
liquid introduction at trigger-points.3,15 The frequency of 
ROP analgesic block applied subcutaneously to TN patients 
followed the practice guidelines for the interventional 
techniques:40 a patient received an injection at intervals 
of no less than 1 week, which was the period chosen to 
mediate between each ROP (or saline)  administration. 
The MVD protocol is still considered the first-line surgi-
cal treatment for medically unresponsive TN,57–59 mainly 
in younger patients,28 although radiosurgery is the main 
option in radiosurgery centers, especially when applied 
in older people.28
clinical impact of the three Tn  
treatment protocols
Since a 2-point decrease in the mean NRS scale 
(0–10 scale) is considered the minimum clinical relevant 
difference in pain intensity when comparing the effect 
of 2 treatments,43–45 the GBP+ROP, CBZ, and MVD pro-
tocols, by decreasing pain intensity in 6.1, 5.3, and 5.7 
(respectively) points, were clinically effective in reducing 
pain at month 6; additionally, all protocols also reduced 
significantly the number of daily pain crises. These results 
are in accordance with the literature in terms of efficacy 
in controlling pain in TN.3,15,37 Since this study is a retro-
spective and observational evaluation of 3 sets of patients 
who were randomly allocated in 3  different studies, the 
degrees of reduction of pain values cannot be compared 
among protocols (both NRS scale values and number of 
daily pain crises). Another study has compared outcomes 
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in a group of patients who have had both pharmacological 
and surgical TN treatments. Patients treated with oxcar-
bazepine and different surgeries (MVD and Gasser gan-
glion surgery) were compared and patients would prefer 
to have had surgery before.60 Although sensory deficits 
and necessity for repeating surgery have occurred, pain 
relief was significantly longer after surgery than after 
pharmacological treatment, recurrence being 10 months 
after oxcarbazepine and 28 months after surgery. As these 
data cannot be extrapolated to other anticonvulsivant 
drugs, similar comparative studies should be performed 
in the future.
When comparing the effect of GBP+ROP, CBZ and 
MVD protocols between baseline (day 0) and month 6, 
other indications of the clinical outcome can be performed 
using specific questionnaires. The functional analysis of 
quality of life measured by the SIP indicated that func-
tional improvement was significant after pharmacological 
 protocols but not after MVD. This may result from the 
several patients with sensory deficits occurring after the 
latter, which may counteract the functional improvement 
 resulting from pain control. This study shows that, in addi-
tion to GBP+ROP protocol,3 CBZ improves functionality. 
Only 1 paper has evaluated SIP in a surgical context,61 
indicating improvement in TN patients after epidural motor 
cortex stimulation. HADS showed that only patients sub-
mitted to MVD showed a significant improvement in both 
anxiety and depression scores, probably because patients 
who are hospitalized for surgery have a very high degree of 
anxiety and expectation.62 On the contrary, all GBP+ROP 
and CBZ patients were completely satisfied with the treat-
ment protocol and the clinical team, whereas some MVD 
patients were unsatisfied or acceptably  satisfied with the 
treatment protocol; this may result from the sequelae that 
were present in a significant number of MVD patients. 
Finally, CBZ protocol resulted in dizziness only in some 
patients and GBP+ROP patients showed virtually no 
adverse side effects.
Another important therapeutical improvement of 
GBP+ROP and MVD protocols is the demonstration of a 
large decrease in the daily dose of anticonvulsivant drug 
intake from baseline (day 0), both at the end of the treat-
ment (day 29, GBP+ROP protocol) and, even further, after 
the 5-month follow-up (month 6).3 On the contrary, in CBZ 
monotherapy a progressive increase was observed in daily 
CBZ dosage.15 These data show that the clinical results of NT 
treatment with GBP+ROP and MVD are superior to those 
for CBZ monotherapy, because the significantly lower dose 
of drugs used strongly decreased the presence/intensity of 
adverse side effects.
Direct costs
The data presented in this study point to a much higher 
cost of the surgical approach to TN treatment than the 
other two pharmacological protocols. This results directly 
from the high costs of surgical intervention and hospital 
stay before, during, and after the MVD. However, during 
follow-up, the maintenance of pain control in TN patients 
submitted to surgery requires less medical therapy than the 
other two protocols. Although being clearly the less expen-
sive treatment during the first 4-week treatment period, the 
GBP+ROP protocol tends to be the most expensive therapy 
after stabilization of TN pain control (follow-up) due to the 
higher cost of GBP drug (Neurontin® [Pfizer Laboratories, 
Porto Salvo, Portugal] or Gabamox® [Pentafarma, Prior 
Velho, Portugal]) versus CBZ drug (Tegretol® [Novartis 
Farma, Sintra, Portugal]). Data suggest that larger follow-up 
periods may reveal that the MVD approach is less expensive 
than the drug therapies. Only a few  studies have evaluated 
the effects of drugs in the reduction of costs in TN,34 or have 
compared the cost of different TN surgical protocols.32,33 
In accordance with a less expensive experience resulting 
from MVD surgery, in a comparison between this surgery, 
glycerol rhizotomy, and stereotactic radiosurgery, it was 
shown that in longer follow-up intervals MVD is predicted 
to be the most cost-effective surgery and should be consid-
ered the preferred operation for patients.32 However, recent 
data point to cyberknife radiosurgery being a cost-saving 
alternative to MVD.33 The only study showing cost-saving 
using drug therapy in TN point to the use of pregabalin.34 
Finally, to the best of our knowledge, the present paper is the 
first attempt to compare clinical outcomes and costs among 
pharmacological protocols and the most common surgical 
approach in TN (excluding radiosurgery centers).
Limitations of the study
This study has some limitations. First, the rates of pain 
improvement in the three groups of patients are not 
directly comparable; although they were randomly selected, 
patients allocated to the CBZ and GBP+ROP branches were 
recruited from 2 different studies3,15 and only the MVD 
patients were retrospectively selected for this specific study. 
Second, patients from MVD protocol had pain scores in the 
NRS scales significantly higher at baseline (day 0) than 
patients from CBZ and GBP+ROP protocols; the difference 
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in patients’ characteristics is explained by the fact that MVD 
is usually not seen as an alternative to pharmacological 
protocols but, rather, as a second-line strategy whenever 
first-line or second-line drugs cause intolerable side effects 
or cannot control TN pain. Accordingly, the group of MVD 
patients had already failed the pharmacological therapy and 
thus had also longer pain periods than the patients from the 
other two protocols. Third, the complication rate of MVD 
patients may be higher than that in other published series, 
which is likely to be due to the small number of patients 
included in the study. Fourth, the cost analysis does not 
include costs associated with loss of productivity by patients 
during the admission and evaluation periods at the Hospital/
Pain Unit and insurance contributions (indirect costs). Fifth, 
although the pain intensity and number of paroxysmal crises 
were significantly improved after 6 months of treatment 
with CBZ+ROP, CBZ, and MVD protocols, the follow-up 
period may not have been sufficient to determine the poten-
tial long-term effects of the treatments. Consequently, stud-
ies with larger numbers of patients, sequential allocation 
of patients for surgical and pharmacological branches, and 
longer follow-up periods should be undertaken to verify 
data obtained in the present study.
Conclusion
Although CBZ has long been known, and is still recog-
nized, as the first-line drug choice for pain control in TN, an 
improvement of second-line drug therapy has been achieved 
by combining GBP intake with the peripheral analgesic block 
of TN trigger-points by ROP (GBP+ROP). Whenever phar-
macological approaches fail, microvascular decompression 
is a surgical method of choice (MVD). We show that the 
three protocols resulted in a clinically significant improve-
ment in pain, as shown by the NRS scale and number of 
paroxysmal pain crises, which were accompanied by a clear 
decrease in the daily CBZ/GBP dosage needed for TN pain 
control, with a consequent reduction in associated adverse 
side effects. The cost analysis indicates that the first 4-week 
period of treatment (or admission, surgery, and treatment in 
MVD patients) results in GBP+ROP being by far the least 
expensive protocol and MVD the most expensive. However, 
over time (follow-up), GBP+ROP protocol tended to be the 
most costly treatment and MVD the least expensive (very 
similar to CBZ protocol). Longer follow-up periods will 
potentially indicate that MVD is a less costly approach to 
TN than the drug treatments.
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